Journal of the Pediatric Infectious Diseases Society, 2024-09, Vol.13 (9), p.496-500
2024
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial
- Ist Teil von
- Journal of the Pediatric Infectious Diseases Society, 2024-09, Vol.13 (9), p.496-500
- Ort / Verlag
- US: Oxford University Press
- Erscheinungsjahr
- 2024
- Quelle
- Oxford Journals 2020 Medicine
- Beschreibungen/Notizen
- Abstract We characterized population pharmacokinetics in 42 African children receiving once-daily 25 mg (14 to <20 kg) or 50 mg (>20 kg) dolutegravir. Coadministration with emtricitabine and tenofovir alafenamide reduced dolutegravir bioavailability by 19.6% (95% confidence interval: 8.13%–30.8%) compared with zidovudine or abacavir with lamivudine. Nevertheless, concentrations remained above efficacy targets, confirming current dosing recommendations.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2048-7207, 2048-7193eISSN: 2048-7207DOI: 10.1093/jpids/piae076Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11424990
- Format
- –
- Schlagworte
- Adenine - analogs & derivatives, Adenine - pharmacokinetics, Adenine - therapeutic use, Adolescent, Alanine - analogs & derivatives, Alanine - pharmacokinetics, Alanine - therapeutic use, Anti-HIV Agents - administration & dosage, Anti-HIV Agents - blood, Anti-HIV Agents - pharmacokinetics, Anti-HIV Agents - therapeutic use, Biological Availability, Brief Reports, Child, Child, Preschool, Dideoxynucleosides - administration & dosage, Dideoxynucleosides - pharmacokinetics, Dideoxynucleosides - therapeutic use, Drug Interactions, Drug Therapy, Combination, Emtricitabine - administration & dosage, Emtricitabine - pharmacokinetics, Emtricitabine - therapeutic use, Female, Heterocyclic Compounds, 3-Ring - administration & dosage, Heterocyclic Compounds, 3-Ring - blood, Heterocyclic Compounds, 3-Ring - pharmacokinetics, Heterocyclic Compounds, 3-Ring - therapeutic use, HIV Infections - drug therapy, HIV Integrase Inhibitors - administration & dosage, HIV Integrase Inhibitors - pharmacokinetics, HIV Integrase Inhibitors - therapeutic use, Humans, Lamivudine - administration & dosage, Lamivudine - pharmacokinetics, Lamivudine - therapeutic use, Male, Oxazines - pharmacokinetics, Piperazines - pharmacokinetics, Pyridones - pharmacokinetics, Tenofovir - pharmacokinetics, Tenofovir - therapeutic use, Zidovudine - administration & dosage, Zidovudine - pharmacokinetics, Zidovudine - therapeutic use